Bonal Intl Inc (BONL) 1.7900 $BONL Bonal International,

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bonal Intl Inc (BONL) 1.7900 $BONL

Bonal International, Inc. Appoints New Auditing Firm
PR Newswire - Fri Mar 20, 8:00AM CDT
Bonal International, Inc. (OTC: BONL) has announced that its board of directors has selected a new accounting firm to audit its financial statements and prepare its tax returns. The newly selected firm is Godfrey, Hammel, Danneels and Company P.C. ("GHD", of St. Clair Shores, Michigan. Mr. Thomas E. Hebel, the Company's President, noted, "The GHD team of professional auditors and consultants is a good fit for Bonal International," and further noted that there were no disputes with the previous accounting firm. GHD will audit the Company's financial statements beginning with fiscal year 2015.

Bonal International announces dividend of USD0.05 per share
M2 - Thu Feb 19, 3:59AM CST
Bonal International Inc (OTC:BONL), the holding company of a patent holder and provider of sub-harmonic vibratory stress relief and weld conditioning technology products, on Wednesday declared a dividend of USD0.05 per share.

Bonal International, Inc. Declares Dividend
PR Newswire - Wed Feb 18, 9:18AM CST
Bonal International, Inc. (OTC: BONL) has announced a dividend of $0.05 per share. This is the seventeenth dividend which represents the tenth consecutive fiscal year Bonal has declared a dividend and is the fourth dividend paid this fiscal year. The dividend is payable on March 10, 2015 to shareholders of record as of the close of business on March 4, 2015.

Bonal International Posts Solid Third Quarter
PR Newswire - Tue Feb 17, 11:13AM CST
Bonal International, Inc. (OTC: BONL) announced a solid third quarter with a 16 percent increase in revenue to $505,519 from last year's $436,626. Net income increased significantly to $158,475, whereas the previous year's third quarter was a loss. Earnings per share also showed an increase of $0.09 compared to the previous year's $0.01 loss. Reflecting Bonal's performance this quarter, the nine-month total of $1,558,520 represents a one percent increase from last year's $1,537,028. Net income for the first nine months of the fiscal year is $296,718, up from $146,257 one year ago. Earnings per share rose to $0.17 from last year's $0.08.

Bonal International Reports Second Quarter Results for Fiscal Year 2015
PR Newswire - Wed Nov 26, 11:08AM CST
Bonal International, Inc., (OTC: BONL) announced revenue for the second quarter ended September 30, 2014 of $434,857 down 25.2 percent from the second quarter ended September 30, 2013. Net income earned during the second quarter 2014 was $28,190 down from $114,148 earned in the second quarter 2013. Net income represented a 6.5 percent profit. Earnings per share were $0.02 per share in the second quarter 2014 compared to $0.07 per share for the second quarter last year.

Bonal International announces special dividend of USD0.05 per share
M2 - Fri Oct 24, 3:38AM CDT
The board of directors of Bonal International Inc (OTC:BONL), the holding company of patent holder and provider of sub-harmonic vibratory stress relief and weld conditioning technology, approved a special, non-reoccurring, dividend of USD0.05 per share, the company reported on Thursday.

Bonal International declares $0.05 dividend
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:22AM CDT


Bonal International, Inc. Declares Special Dividend
PR Newswire - Thu Oct 23, 8:50AM CDT
The Board of Directors of Bonal International, Inc. (OTC: BONL) has authorized a special, non-reoccurring, dividend of $0.05 per share. This special dividend is payable on November 19, 2014 to shareholders of record as of the close of business on November 5, 2014.

Bonal International Reports First Quarter Results
PR Newswire - Tue Aug 12, 10:11AM CDT
Bonal International, Inc. (OTC: BONL) announced significant increases in revenue and net income with today's release of its first quarter results. Revenue rose to $618,144 in the first quarter, a 19 percent increase from $519,077 in the first quarter last year. Net income doubled to $110,054 compared to $54,544 from last year's first quarter net income. Earnings per share increased to $0.06 compared to $0.03 last year.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading